Quantum Biopharma Announces Positive Phase 1 Trial Results for Lucid-MS Multiple Sclerosis Treatment

Quantum BioPharma has received the clinical study report for its Phase 1 Multiple Ascending Dose trial of Lucid-21-302, a potential treatment for multiple sclerosis. The study found that the drug was safe and well-tolerated in healthy participants. The company plans to advance the clinical development of Lucid-MS and launch efficacy trials in patients with MS. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action.

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received the clinical study report (CSR) for its Phase 1 Multiple Ascending Dose (MAD) trial of Lucid-MS, a potential treatment for multiple sclerosis (MS). The trial, conducted by the company's subsidiary, Huge Biopharma Australia Pty Ltd., concluded that the drug was safe and well-tolerated in healthy participants [1].

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action. It is designed to prevent and reverse myelin degradation, which is a hallmark of MS and other neurogenerative diseases. The CSR allows Quantum BioPharma to advance the clinical development of Lucid-MS and launch efficacy trials in patients with MS [1].

"We are thrilled that we now have the CSR for the Phase 1 MAD trial and that Lucid-MS was found to be safe and well-tolerated in healthy participants," said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma. "The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug (IND) application with the FDA" [1].

The company is preparing for the launch of efficacy trials in patients with MS, which is very exciting. This compound follows a novel non-immunomodulatory mechanism, and Quantum BioPharma is very excited to be planning human efficacy trials [1].

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc. [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/05/3127241/0/en/Quantum-Biopharma-Announces-Positive-Results-of-the-Clinical-Study-Report-CSR-for-the-Phase-1-Multiple-Ascending-Dose-MAD-Clinical-Trial-of-Experimental-Multiple-Sclerosis-Drug-Luc.html